| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 08/30/2001 | WO2001062942A2 MATERIALS AND METHODS INVOLVING HYBRID VASCULAR ENDOTHELIAL GROWTH FACTOR DNAs AND PROTEINS AND SCREENING METHODS FOR MODULATORS |
| 08/30/2001 | WO2001062932A1 Antagonistic selective binding agents of osteoprotegerin binding protein |
| 08/30/2001 | WO2001062931A2 ANTI-EGFRvIII SCFVS WITH IMPROVED CYTOTOXICITY AND YIELD, IMMUNOTOXINS BASED THEREON, AND METHODS OF USE THEREOF |
| 08/30/2001 | WO2001062923A2 Transporters and ion channels |
| 08/30/2001 | WO2001062920A2 Compositions and methods for diagnosis and therapy of malignant mesothelioma |
| 08/30/2001 | WO2001062919A1 Modified fluorescent proteins |
| 08/30/2001 | WO2001062905A2 Integrin antagonists |
| 08/30/2001 | WO2001062796A1 Ccr2-64i, polymorphic variant of the human ccrs receptor and its use in the diagnostic and treatment of atherosclerosis |
| 08/30/2001 | WO2001062793A2 Estrogen receptor beta variants and methods of detection thereof |
| 08/30/2001 | WO2001062792A2 Cancer treatment and prognosis involving hes-1 protein |
| 08/30/2001 | WO2001062779A2 New transcription factor carp-2 |
| 08/30/2001 | WO2001062778A2 Tumour-specific animal proteins |
| 08/30/2001 | WO2001062765A2 Small molecule modulators of g protein-coupled receptor six |
| 08/30/2001 | WO2001062745A1 Substituted 8, 8a-dihydro-3ah-indeno[1,2-d]thiazoles, a method for their production and their use as medicaments |
| 08/30/2001 | WO2001062725A2 Methods and compositions for inhibiting angiogenesis |
| 08/30/2001 | WO2001062721A1 Novel use of phenylheteroalkylamine derivatives |
| 08/30/2001 | WO2001062713A1 Novel phenylheteroalkylamine derivatives |
| 08/30/2001 | WO2001062704A1 Novel use of phenylheteroalkylamine derivatives |
| 08/30/2001 | WO2001062341A2 Combination product for the treatment of obesity |
| 08/30/2001 | WO2001062312A1 Foam-forming wound dressing |
| 08/30/2001 | WO2001062300A2 Caspase activated prodrugs therapy |
| 08/30/2001 | WO2001062297A1 Compositions and methods for enhancing drug delivery across biological membranes and tissues |
| 08/30/2001 | WO2001062295A1 Drugs containing combined active ingredients |
| 08/30/2001 | WO2001062291A1 Compositions for preventing and treating digestive diseases |
| 08/30/2001 | WO2001062290A2 Methods and compositions for improving sleep |
| 08/30/2001 | WO2001062289A2 Photodynamic cellular and acellular organism eradication utilizing a photosensitive material and surfactant |
| 08/30/2001 | WO2001062288A1 Membrane estrogen receptor-directed therapy in breast cancer |
| 08/30/2001 | WO2001062286A1 Novel antibody with specificity for colon cancer |
| 08/30/2001 | WO2001062285A1 Use of il-18 inhibitors |
| 08/30/2001 | WO2001062281A1 Pai-2 conjugates for the treatment and imaging of cancer |
| 08/30/2001 | WO2001062275A1 Adjuvant treatment by in vivo activation of dendritic cells |
| 08/30/2001 | WO2001062270A2 Method for treating hashimoto's thyroiditis |
| 08/30/2001 | WO2001062266A2 Use of dpp-iv inhibitors for the treatment of diabetes |
| 08/30/2001 | WO2001062261A1 Metalloproteinase inhibitors for the treatment of respiratory diseases |
| 08/30/2001 | WO2001062259A1 Method of treatment of prostate cancer |
| 08/30/2001 | WO2001062257A2 Bupropion metabolites and methods of their synthesis and use |
| 08/30/2001 | WO2001062255A1 Antiviral azaindole derivatives |
| 08/30/2001 | WO2001062252A1 Tyrosine kinase inhibitors |
| 08/30/2001 | WO2001062251A1 Tyrosine kinase inhibitors |
| 08/30/2001 | WO2001062237A2 Compositions for the treatment of alopecia and other disorders of the pilosebaceous apparatus |
| 08/30/2001 | WO2001062236A2 New drug combinations comprising a norepinephrine reuptake inhibitor and an antimuscarinic agent |
| 08/30/2001 | WO2001062235A2 A composition comprising camptothecin and a pyrimidine derivative for the treatment of cancer |
| 08/30/2001 | WO2001062234A2 Dosing regimen |
| 08/30/2001 | WO2001062231A1 Antibiotic composition with inhibitor |
| 08/30/2001 | WO2001062229A1 Therapeutic product, use and formulation thereof |
| 08/30/2001 | WO2001062228A1 Method for transdermal or intradermal delivery of molecules |
| 08/30/2001 | WO2001062195A1 Antibiotic and antifungal compositions |
| 08/30/2001 | WO2001062108A1 Water containing soluble fiber |
| 08/30/2001 | WO2001013927A3 Improved topical compositions containing probiotic bacteria, spores, and extracellular products and uses thereof |
| 08/30/2001 | WO2001013907A3 Pharmaceutical combination for the treatment of viral infections containing a calcium channel blocker and a quinoline |
| 08/30/2001 | WO2001013031A3 Dose of an angiogenic factor and method of administering to improve myocardial blood flow |
| 08/30/2001 | WO2001012236A3 Methods, compositions and kits for promoting recovery from damage to the central nervous system |
| 08/30/2001 | WO2001012228A3 Compositions for treating viral infections, and methods therefor |
| 08/30/2001 | WO2001010900A3 Globular assembly of amyloid beta protein and uses thereof |
| 08/30/2001 | WO2000041719A9 Methods of using a neurotrophin and its analogues for the treatment of gastrointestinal hypomotility disorders |
| 08/30/2001 | WO2000040733A9 Human cyclic nucleotide pdes |
| 08/30/2001 | WO2000040614A9 Characterization of the soc/crac calcium channel protein family |
| 08/30/2001 | WO2000040597A9 Method and composition for angiogenesis inhibition |
| 08/30/2001 | US20010018524 Novel compounds for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof |
| 08/30/2001 | US20010018511 Anticancer agent |
| 08/30/2001 | US20010018456 Use of a RAR-gamma-specific agonist ligand for increasing the rate of apoptosis |
| 08/30/2001 | US20010018445 Thalidomide |
| 08/30/2001 | US20010018434 Administering an antiestrogen compound |
| 08/30/2001 | US20010018433 Administering a bisphosphonate compound; prostaglandin antagonist |
| 08/30/2001 | US20010018417 Of sodium lauryl sulfate, a buffering agent to provide acidic pH when the mixture is added to water, and colloidal silica; mixture added to animal feeds |
| 08/30/2001 | US20010018069 Oral administration of fast-dispersing/disintegrating forumulation of dopamine agonist, antiemetic, opioid antagonist, testosterone, and flavored carrier; pregastric absorption; side effect reduction |
| 08/30/2001 | US20010018068 Water insoluble substrate comprising creped nonwoven layer and cleansing component (lathering surfactant); cleaning/ conditioning skin/hair; disposable; materials handling |
| 08/30/2001 | US20010018065 Administering drugs comprised of antibiotic, carrier, and oligosaccharide-support which binds and removes shiga-like toxins from gastrointestinal tract; Escherichia; enterotoxins; antidiarrhetics |
| 08/30/2001 | US20010018054 Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesis |
| 08/30/2001 | US20010018041 Lymphomas, leukemia |
| 08/30/2001 | DE10008274A1 Substituierte 8,8a-Dihydro-3aH-indeno[1,2-d]thiazole, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel Substituted 8,8a-dihydro-3aH-indeno [1,2-d] thiazoles, process for their preparation and their use as medicaments |
| 08/30/2001 | CA2683009A1 Use of il-18 inhibitors |
| 08/30/2001 | CA2406871A1 Methods and compositions for the treatment of alopecia and other disorders of the pilosebaceous apparatus |
| 08/30/2001 | CA2401356A1 Combination drug |
| 08/30/2001 | CA2401195A1 Pai-2 conjugates for the treatment and imaging of cancer |
| 08/30/2001 | CA2401113A1 Transporters and ion channels |
| 08/30/2001 | CA2401096A1 Methods and compositions for inhibiting angiogenesis |
| 08/30/2001 | CA2401070A1 Compositions and methods for diagnosis and therapy of malignant mesothelioma |
| 08/30/2001 | CA2401063A1 Solution and crystal structures of mmp-13 active site and uses thereof |
| 08/30/2001 | CA2400948A1 Materials and methods involving hybrid vascular endothelial growth factor dnas and proteins |
| 08/30/2001 | CA2400923A1 Tyrosine kinase inhibitors |
| 08/30/2001 | CA2400875A1 Tyrosine kinase inhibitors |
| 08/30/2001 | CA2400874A1 Membrane estrogen receptor-directed therapy in breast cancer |
| 08/30/2001 | CA2400867A1 Method of screening compounds for biological activity |
| 08/30/2001 | CA2400842A1 Novel compounds |
| 08/30/2001 | CA2400831A1 Estrogen receptor beta variants and methods of detection thereof |
| 08/30/2001 | CA2400797A1 Therapeutic agents |
| 08/30/2001 | CA2400794A1 New transcription factor carp-2 |
| 08/30/2001 | CA2400708A1 Methods and compositions for improving sleep |
| 08/30/2001 | CA2400692A1 Substituted 8, 8a-dihydro-3ah-indeno[1,2-d]thiazoles, a method for their production and their use as medicaments |
| 08/30/2001 | CA2400661A1 Novel antibody with specificity for colon cancer |
| 08/30/2001 | CA2400642A1 Modified fluorescent proteins |
| 08/30/2001 | CA2400099A1 Compositions and methods for enhancing drug delivery across biological membranes and tissues |
| 08/30/2001 | CA2400040A1 Integrin antagonists |
| 08/30/2001 | CA2399442A1 New drug combinations |
| 08/30/2001 | CA2399418A1 Metalloproteinase inhibitors for the treatment of respiratory diseases |
| 08/30/2001 | CA2399298A1 Use of il-18 inhibitors |
| 08/30/2001 | CA2399255A1 Caspase activated prodrugs therapy |
| 08/30/2001 | CA2399211A1 Foam-forming wound dressing |
| 08/30/2001 | CA2397558A1 Dosing regimen |